[go: up one dir, main page]

DK2441466T3 - MIC-1-inhiberende middel - Google Patents

MIC-1-inhiberende middel

Info

Publication number
DK2441466T3
DK2441466T3 DK11183884.3T DK11183884T DK2441466T3 DK 2441466 T3 DK2441466 T3 DK 2441466T3 DK 11183884 T DK11183884 T DK 11183884T DK 2441466 T3 DK2441466 T3 DK 2441466T3
Authority
DK
Denmark
Prior art keywords
mic
inhibitor
Prior art date
Application number
DK11183884.3T
Other languages
English (en)
Inventor
Samuel Norbet Briet
Asne Rhoda Bauskin
Original Assignee
St Vincents Hosp Sydney
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35149777&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2441466(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from AU2004901957A external-priority patent/AU2004901957A0/en
Application filed by St Vincents Hosp Sydney filed Critical St Vincents Hosp Sydney
Application granted granted Critical
Publication of DK2441466T3 publication Critical patent/DK2441466T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/02—Nutritional disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/30—Psychoses; Psychiatry
    • G01N2800/303—Eating disorders, e.g. anorexia, bulimia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DK11183884.3T 2004-04-13 2005-04-13 MIC-1-inhiberende middel DK2441466T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2004901957A AU2004901957A0 (en) 2004-04-13 Method for modulating appetite
EP05729508.1A EP1734986B1 (en) 2004-04-13 2005-04-13 Method for modulating appetite

Publications (1)

Publication Number Publication Date
DK2441466T3 true DK2441466T3 (da) 2014-10-27

Family

ID=35149777

Family Applications (2)

Application Number Title Priority Date Filing Date
DK11183884.3T DK2441466T3 (da) 2004-04-13 2005-04-13 MIC-1-inhiberende middel
DK15163748.5T DK2929891T3 (da) 2004-04-13 2005-04-13 Fremgangsmåde til modulering af appetitten

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK15163748.5T DK2929891T3 (da) 2004-04-13 2005-04-13 Fremgangsmåde til modulering af appetitten

Country Status (11)

Country Link
US (7) US8192735B2 (da)
EP (4) EP2441466B1 (da)
JP (4) JP5448338B2 (da)
CA (2) CA2561877C (da)
CY (1) CY1115731T1 (da)
DK (2) DK2441466T3 (da)
ES (3) ES2518865T3 (da)
PL (2) PL2441466T3 (da)
PT (2) PT2441466E (da)
SI (1) SI2441466T1 (da)
WO (1) WO2005099746A1 (da)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2441466T3 (pl) * 2004-04-13 2015-01-30 St Vincents Hospital Sydney Ltd Środek hamujący MIC-1
BRPI0715126B8 (pt) * 2006-08-04 2021-07-27 Medizinische Hochschule Hannover métodos para avaliação do risco de intervenções cardíacas e usos à base de gdf-15
CA2694863A1 (en) * 2007-08-16 2009-02-19 Garvan Institute Of Medical Research Agents and methods for modulating macrophage inhibitory cytokine (mic-1) activity
JP2011502106A (ja) * 2007-10-09 2011-01-20 セントビンセンツ ホスピタル シドニー リミテッド マクロファージ阻害性サイトカイン−１を除去又は不活性化して悪液質を治療する方法
CN102203619B (zh) * 2008-10-31 2015-12-16 圣文森特医院悉尼有限公司 慢性肾病中的预测方法
CN103533951B (zh) 2011-04-08 2017-04-19 安姆根有限公司 使用生长分化因子15(gdf‑15)治疗或改善代谢障碍的方法
CN104204218A (zh) 2012-01-26 2014-12-10 安姆根有限公司 生长分化因子15 (gdf-15)多肽
CA2862516C (en) 2012-03-27 2023-02-14 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
JP2015532271A (ja) 2012-09-26 2015-11-09 ユリウス・マクシミリアンス−ウニヴェルジテート・ヴュルツブルクＪｕｌｉｕｓ Ｍａｘｉｍｉｌｉａｎｓ−Ｕｎｉｖｅｒｓｉｔａｅｔ Ｗｕｅｒｚｂｕｒｇ 増殖分化因子１５（ｇｄｆ−１５）に対するモノクローナル抗体
EP3689370A1 (en) * 2012-12-21 2020-08-05 Aveo Pharmaceuticals Inc. Anti-gdf15 antibodies
JP6272907B2 (ja) 2013-01-30 2018-01-31 エヌジーエム バイオファーマシューティカルズ インコーポレイテッド 代謝障害の処置における組成物及び使用方法
US9161966B2 (en) 2013-01-30 2015-10-20 Ngm Biopharmaceuticals, Inc. GDF15 mutein polypeptides
CN105980400B (zh) 2013-07-31 2021-05-07 美国安进公司 生长分化因子15(gdf-15)构建体
LT3653644T (lt) 2014-03-26 2024-01-25 Julius-Maximilians-Universität Würzburg Monokloniniai antikūnai prieš augimo ir diferenciacijos faktorių 15 (gdf- 15), ir jų panaudojimas taikant vėžio kacheksijos ir vėžio gydymą
GB2524552B (en) * 2014-03-26 2017-07-12 Julius-Maximilians-Universitãt Wurzburg Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and use thereof for treating cancer
GB2524553C (en) * 2014-03-26 2017-07-19 Julius-Maximilians-Universitãt Würzburg Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and uses thereof for treating cancer cachexia
JP6768527B2 (ja) * 2014-06-20 2020-10-14 アベオ ファーマシューティカルズ， インコーポレイテッド Ｇｄｆ１５調節剤を用いた慢性腎臓病及びその他の腎機能不全の治療
WO2015196142A1 (en) * 2014-06-20 2015-12-23 Aveo Pharmaceuticals, Inc. Treatment of congestive heart failure and other cardiac dysfunction using a gdf15 modulator
US20170107248A1 (en) * 2014-06-23 2017-04-20 Novartis Ag Site specific protein modifications
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
JP6696915B2 (ja) 2014-06-24 2020-05-20 ノヴォ ノルディスク アー／エス Ｍｉｃ−１融合タンパク質及びその使用
TWI710570B (zh) 2014-07-30 2020-11-21 美商Ｎｇｍ生物製藥公司 用於治療代謝異常之組成物及方法
EP3197493B1 (en) 2014-09-25 2021-03-10 Aveo Pharmaceuticals Inc. Methods of reversing cachexia and prolonging survival comprising administering a gdf15 modulator and an anti-cancer agent
AP2017009828A0 (en) 2014-10-31 2017-03-31 Ngm Biopharmaceuticals Inc Compositions and methods of use for treating metabolic disorders
WO2016102580A1 (en) * 2014-12-22 2016-06-30 Novo Nordisk A/S Alpha-1-antitrypsin (a1at) fusion proteins and uses thereof
GB201517528D0 (en) 2015-10-02 2015-11-18 Julius Maximillians Universitãt Würzburg GDF-15 as a diagnosis marker for melanoma
FI3356827T3 (fi) 2015-10-02 2024-01-03 Univ Wuerzburg J Maximilians GDF-15 diagnostisena markkerina immuunivasteen vapauttajilla annetun hoidon hoitovasteen ennustamiseksi
BR112018006218A2 (pt) 2015-10-02 2018-10-09 Univ Wuerzburg J Maximilians iinibidores de hgdf-15, seus usos, composição, kit, combinações e método in vitro para determinar se uma substância de interesse é um inibidor de hgdf-15
WO2017121865A1 (en) 2016-01-15 2017-07-20 Novo Nordisk A/S Mic-1 receptor and uses thereof
WO2017150314A1 (ja) * 2016-02-29 2017-09-08 公立大学法人横浜市立大学 去勢抵抗性前立腺癌を検出する方法及び検出試薬
SG11201807279QA (en) 2016-03-31 2018-09-27 Ngm Biopharmaceuticals Inc Binding proteins and methods of use thereof
US11312766B2 (en) 2016-04-27 2022-04-26 Novartis Ag Antibodies against growth differentiation factor 15 and uses thereof
KR102433503B1 (ko) 2016-05-24 2022-08-18 노보 노르디스크 에이/에스 Mic-1 화합물 및 이것의 사용
EP3526346A1 (en) * 2016-10-12 2019-08-21 Janssen Biotech, Inc. Methods for screening for modulators of gdf15-like biological activity
AU2017371382A1 (en) * 2016-12-06 2019-06-13 St Vincent's Hospital Sydney Limited Treatment of obesity and eating disorders
GB201700567D0 (en) 2017-01-12 2017-03-01 Genagon Therapeutics Ab Therapeutic agents
TWI710377B (zh) 2017-05-23 2020-11-21 丹麥商諾佛 儂迪克股份有限公司 Ｍｉｃ－１化合物及其用途
WO2019004550A1 (ko) * 2017-06-26 2019-01-03 강원대학교 산학협력단 Mic-1 단백질에 특이적으로 결합하는 항체 및 이의 용도
JP7127422B2 (ja) 2017-08-30 2022-08-30 東ソー株式会社 癌を検出する方法及び検出試薬
JP2020533302A (ja) 2017-09-10 2020-11-19 ノヴォ ノルディスク アー／エス 肥満の治療において使用するためのｍｉｃ−１およびｇｌｐ−１
MX2020010659A (es) 2018-04-09 2020-10-28 Amgen Inc Proteinas de fusion del factor de diferenciacion de crecimiento 15.
SG11202101502YA (en) 2018-08-20 2021-03-30 Pfizer Anti-gdf15 antibodies, compositions and methods of use
US10706329B2 (en) * 2018-11-13 2020-07-07 CurieAI, Inc. Methods for explainability of deep-learning models
WO2021107603A2 (en) 2019-11-26 2021-06-03 Yuhan Corporation Long-acting gdf15 fusion protein and pharmaceutical composition comprising same
IL302646A (en) 2020-11-10 2023-07-01 Catalym Gmbh Anti-GDF15 antibody and dosage regimen for cancer treatment
JP2024511853A (ja) 2021-03-31 2024-03-15 カイマブ・リミテッド Ｇｄｆ１５シグナル伝達の治療的阻害剤
CA3219645A1 (en) 2021-05-21 2022-11-24 Yuhan Corporation Composition for combination therapy comprising growth differentiation factor-15 variant and glucagon-like peptide-1 receptor agonist
CA3219685A1 (en) 2021-05-21 2022-11-24 Seyoung LIM Composition for preventing or treating non-alcoholic fatty liver disease or non-alcoholic steatohepatitis comprising growth differentiation factor-15 variant
US20250019427A1 (en) 2021-08-10 2025-01-16 Byomass Inc. Anti-gdf15 antibodies, compositions and uses thereof
WO2023122213A1 (en) 2021-12-22 2023-06-29 Byomass Inc. Targeting gdf15-gfral pathway cross-reference to related applications
WO2023154953A1 (en) 2022-02-14 2023-08-17 Ngm Biopharmaceuticals, Inc. Gdf15 polypeptides for treating and preventing autoimmune diseases

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
CA2225377C (en) 1995-06-22 2013-08-13 St. Vincent's Hospital Sydney Limited Novel tgf-.beta. like cytokine
AU8591198A (en) 1997-07-31 1999-02-22 Johns Hopkins University School Of Medicine, The Growth differentiation factor-15
EP2128260A3 (en) 1998-10-07 2010-06-16 STRYKER CORPORATION (a Michigan corporation) Modified TGF-beta superfamily proteins
ATE384265T1 (de) * 2000-04-20 2008-02-15 St Vincents Hosp Sydney Diagnostischer assay mit dem makrophagen- inhibitorischen-zytokin-1 (mic-1)
AU2001288770A1 (en) * 2000-09-08 2002-03-22 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services A non-steroidal anti-inflammatory drug activated gene with anti-tumorigenic properties
CA2390820A1 (en) * 2002-06-17 2003-12-17 St. Vincent's Hospital Sydney Limited Methods of diagnosis, prognosis and treatment of cardiovascular disease
PL2441466T3 (pl) 2004-04-13 2015-01-30 St Vincents Hospital Sydney Ltd Środek hamujący MIC-1
JP5372380B2 (ja) * 2005-01-24 2013-12-18 ペプスキャン システムズ ベー．フェー． 結合化合物、免疫原性化合物およびペプチド模倣体
SG2014010680A (en) 2009-02-12 2014-04-28 Stryker Corp Peripheral administration of proteins including tgf-beta superfamily members for treatment of systemic disorders and disease

Also Published As

Publication number Publication date
JP5448338B2 (ja) 2014-03-19
JP5806275B2 (ja) 2015-11-10
US20160289320A1 (en) 2016-10-06
PT2929891T (pt) 2020-04-08
HK1168274A1 (en) 2012-12-28
CA2561877A1 (en) 2005-10-27
ES2518865T3 (es) 2014-11-05
JP2014051511A (ja) 2014-03-20
EP2929891A1 (en) 2015-10-14
JP2011190262A (ja) 2011-09-29
DK2929891T3 (da) 2020-05-11
US20180346560A1 (en) 2018-12-06
US20250109192A1 (en) 2025-04-03
ES2555956T3 (es) 2016-01-11
CA2905125A1 (en) 2005-10-27
EP1734986A1 (en) 2006-12-27
EP1734986B1 (en) 2015-11-11
CY1115731T1 (el) 2017-01-25
JP2007532586A (ja) 2007-11-15
PT2441466E (pt) 2014-09-09
PL2929891T3 (pl) 2020-08-24
EP1734986A4 (en) 2009-07-22
EP2441466A1 (en) 2012-04-18
JP5767667B2 (ja) 2015-08-19
US8192735B2 (en) 2012-06-05
EP2774620A1 (en) 2014-09-10
CA2905125C (en) 2017-02-07
US20210340243A1 (en) 2021-11-04
CA2561877C (en) 2017-03-14
US20110123454A1 (en) 2011-05-26
EP2441466B1 (en) 2014-07-23
PL2441466T3 (pl) 2015-01-30
EP2929891B1 (en) 2020-03-11
ES2788868T3 (es) 2020-10-23
US20150183861A1 (en) 2015-07-02
WO2005099746A1 (en) 2005-10-27
SI2441466T1 (sl) 2015-01-30
US20090004181A1 (en) 2009-01-01
US8946146B2 (en) 2015-02-03
HK1215932A1 (en) 2016-09-30
JP2013209376A (ja) 2013-10-10

Similar Documents

Publication Publication Date Title
DK2441466T3 (da) MIC-1-inhiberende middel
FR19C1052I2 (fr) 4-phenylamino-quinazolin-6-yl-amides
NL300881I2 (nl) bezlotoxumab
EP1756259A4 (en) REACTOR SYSTEM WITH AGITATION RESERVOIR
ITMI20040106A1 (it) Poliuretani
DE602004029102D1 (de) Spiegelwinkeleinstellvorrichtung
DE602005013397D1 (de) Radom-struktur
LU91998I2 (fr) Seresto
ATE392425T1 (de) Thiazolyl-dihydro-indazole
IS8531A (is) Steypumótunarvél
DE502005008587D1 (de) Kugelgelenk
EP1774546A4 (en) ASSEMBLY OF A TRANSFORMER COIL
EP1831161A4 (en) 2-METHYLENE-19-nor (20R) -1-ALPHA-HYDROXY-BISHOMOPREGNACALCIFEROL
AT500198B8 (de) Ladewagen
FR2865904B1 (fr) Calecon remonte fesses
DE602004011046D1 (de) Divinylfluorene
DE602004013423D1 (de) Kraftstoffverteilerkomponent
DE502005003159D1 (de) Kettenstichnähvorrichtung
FI20050605A0 (fi) Höyrypuhalluslaatikko
DE602005000183D1 (de) Leitweglenkungsarchitektur
EP1732098A4 (en) BREAKER
DE602005012002D1 (de) Bildaufzeichungselement
FR2875378B1 (fr) Andaineuse
FR2873792B1 (fr) Aerateur
FI6430U1 (fi) Hammasimplanttikiinnike